## GL: Globe Life Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 2.4% below STRENGTH zone (4.0-10.0%); PEG 1.68 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($133.94)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Globe Life Inc. (GL) And Encourages Investors to Connect**
- Source: FOX4KC.com | 20251211T160822 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Globe Life Inc. (NYSE:GL) regarding alleged corporate wrongdoing. The firm encourages investors who purchased Globe Life securities prior to May 8, 2019, and still hold them, to connect to assist with the investigation. This investigation focuses on whether Globe Life and its officers/directors engaged in misconduct.

**2. Globe Life (GL) Stock Trades Up, Here Is Why**
- Source: Finviz | 20251211T200840 | Bullish | Relevance: 98%
- Shares of Globe Life (GL) rose 2.7% after TD Cowen raised its price target on the stock and included it in its "Best Ideas 2026" list, citing the company's attractive and scalable business model. This recent jump follows a previous gain five months ago when the insurer beat earnings estimates and increased its full-year profit forecast. Globe Life is up 23.7% year-to-date and is trading near its 52-week high.

**3. TD Cowen raises Globe Life stock price target to $199 on growth outlook**
- Source: Investing.com India | 20251211T162528 | Bullish | Relevance: 98%
-  TD Cowen has increased its price target for Globe Life (NYSE:GL) to $199, maintaining a Buy rating, due to the insurance company's "attractive, scalable business" and strong growth outlook. The firm included Globe Life in its "Best Ideas 2026" list, highlighting its consistent growth, low underwriting risk, and large addressable market in the underserved lower-middle and middle-income U.S. households. Despite trading at a discount compared to historical averages, the company boasts a perfect Piotroski Score of 9 and has paid dividends for 55 consecutive years, suggesting undervaluation relative to its growth prospects.

**4. Daiwa Securities Group Inc. Cuts Position in Globe Life Inc. $GL**
- Source: MarketBeat | 20251211T094817 | Somewhat-Bullish | Relevance: 98%
-  Daiwa Securities Group Inc. divested 11.9% of its stake in Globe Life Inc. ($GL) in Q2, bringing its total ownership to 65,999 shares valued at $8.20 million, while institutional investors cumulatively own about 81.61% of the company. Globe Life surpassed its quarterly EPS estimates and provided positive FY2025â€“FY2026 EPS guidance, maintaining a "Moderate Buy" consensus rating among analysts with a target price of $160.75. The stock is currently trading around $134.82, showing a market cap of $10.73 billion, a P/E ratio of 9.77, and a quarterly dividend of $0.27.

**5. Globe Life (GL) Stock Trades Up, Here Is Why**
- Source: The Globe and Mail | 20251211T200832 | Bullish | Relevance: 98%
-  Shares of Globe Life (NYSE:GL) rose 2.7% after TD Cowen increased its price target to $199 from $182, maintaining a "Buy" rating and adding the company to its "Best Ideas 2026" list. Analysts cited the insurer's "attractive, scalable business" which supports steady growth with lower risk. This positive analyst action follows Globe Life's strong second-quarter earnings beat and an increased full-year profit forecast issued five months prior.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | TD Cowen | $199 | $182 | +9% |
| 2025-11-17 | Morgan Stanley | $177 | $179 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | TD Cowen | main | Buy |
| 2025-11-17 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($5.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.7%)
- Blackrock Inc.: 7.2% (-2.1%)
- Invesco Ltd.: 4.8% (-1.9%)
- State Street Corpora: 4.1% (-3.5%)
- Wellington Managemen: 3.5% (-29.0%)

### Key Risks

1. Insider selling cluster: $5.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.68 elevated, pricing in significant growth expectations. Forward P/E 9.3x stretched relative to 3% growth. Quality metrics strong (ROE 22%, margin 19%). Balance sheet: strong liquidity (2.8x). Insider selling cluster ($5.4M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.3B |
| Beta | 0.48 |
| 52W Range | $103.71 - $147.83 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.68 |
| Forward P/E | 9.3 |
| Current P/E | 9.5 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.0% to 2.4% (+5.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >4.0% for momentum thesis). MRS_5 at 3.5% confirms short-term momentum alignment. AM_20 at 4.7% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.42% (CS: 62) | Neutral |
| RSI_14 | 67.1 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.071x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $139.04
- **Stop Loss:** $133.94 (3.7% risk)
- **Target:** $144.14 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 270
- **Position Value:** $37,540.80
- **Portfolio %:** 37.54%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $3.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.54 | $4.81 | +5.9% |
| 2025Q2 | $3.25 | $3.27 | +0.8% |
| 2025Q1 | $3.24 | $3.07 | -5.2% |
| 2024Q4 | $3.12 | $3.14 | +0.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*